[1] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ.
[2] European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol,2017,67(2):370-398.
[3] Liaw YF,Sheen IS,Chen TJ,et al.Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection:a prospective study. Hepatology,1991,13:627-631.
[4] Chu CM,Liaw YF.HBsAg seroclearance in asymptomatic carriers of high endemic areas:appreciably high rates during a long-term follow-up. Hepatology,2007,45:1187-1192.
[5] Yapali S,Talaat N,Lok AS.Management of hepatitis B:our practice and how it relates to the guidelines. Clin Gastroenterol Hepatol,2014,12(1):16-26.
[6] Ning Q,Han M,Sun Y,et al.Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B:a randomised open-label trial (OSST trial). J Hepatol,2014,61(4):777-784.
[7] Hu P,Shang J,Zhang W,et al.HBsAg loss with peg-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog:New switch study. J Clin Transl Hepatol,2018,6(1):25-34.
[8] Papatheodoridis G,Vlachogiannakos I,Cholongitas E,et al.Discontinuation of oral antivirals in chronic hepatitis B:A systematic review. Hepatology,2016,63(5):1481-1492.
[9] Cao J,Chi H,Yu T,et al.Off-treatment hepatitis B virus (HBV) DNA levels and the prediction of relapse after discontinuation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B:A prospective stop study. J Infect Dis,2017,215(4):581-589.
[10] Terrault NA,Lok ASF,McMahon BJ,et al. Update on prevention,diagnosis,and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance. Hepatology,2018,67(4):1560-1599.
[11] Lütgehetmann M1,Bornscheuer T,Volz T,et al. Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice. Gastroenterology,2011,140(7):2074-2083.
[12] Yu S1,Chen J,Wu M,et al. Hepatitis B virus polymerase inhibits RIG-I-and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. Gen Virol,2010,91(Pt 8):2080-2090.
[13] Wei C,Ni C,Song T,et al.The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol,2010,185(2):1158-1168.
[14] Li M,Sun R,Xu L,et al.Kupffer cells support hepatitis B virus-mediated CD8+T cell exhaustion via hepatitis B core antigen-TLR2 interactions in mice. J Immunol,2015,195(7):3100-3109.
[15] Visvanathan K,Skinner NA,Thompson AJ,et al.Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology,2007,45(1):102-110.
[16] Tjwa ET,van Oord GW,Hegmans JP,et al. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J Hepatol,2011,54(2):209-218.
[17] Koumbi L,Pollicino T,Raimondo G,et al.Hepatitis B viral replication influences the expression of natural killer cell ligands. Ann Gastroenterol,2016,29(3):348-357.
[18] Wang S,Chen Z,Hu C,et al.Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation. J Immunol,2013,190(10):5142-5151.
[19] Cheng J,Imanishi H,Morisaki H,et al.Recombinant HBsAg inhibits LPS-induced COX-2 expression and IL-18 production by interfering with the NFkappaB pathway in a human monocytic cell line,THP-1. J Hepatol,2005,43(3):465-471.
[20] Wu J,Zhang XJ,Shi KQ,et al.Hepatitis B surface antigen inhibits MICA and MICB expression via induction of cellular miRNAs in hepatocellular carcinoma cells. Carcinogenesis,2014,35(1):155-163.
[21] Kondo Y,Ninomiya M,Kakazu E,et al.Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection. ISRN Gastroenterol,2013,2013:935295.
[22] Op den Brouw ML,Binda RS,van Roosmalen MH,et al. Hepatitis B virus surface antigen impairs myeloid dendritic cell function:a possible immune escape mechanism of hepatitis B virus. Immunology,2009,126(2):280-289.
[23] Liu J,Li T,Zhang L,et al.The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among Asian chronic hepatitis B patients:A systematic review. Hepatology,2018,[Epub ahead of print].
[24] Boni C,Penna A,Ogg GS,et al.Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B:new perspectives for immune therapy. Hepatology,2001,33:963-971.
[25] Boni C,Penna A,Bertoletti A,et al.Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol,2003,39:595-605.
[26] Boni C,Laccabue D,Lampertico P,et al.Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology,2012,143:963-973e9.
[27] Lauret E,González-Diéguez ML,Rodríguez M,et al.Long-
term outcome in Caucasian patients with chronic hepatitis B virus infection after HBsAg seroclearance. Liver Int,2015,35(1):140-147.
[28] Chen QY,Wang XY,Harrison TJ,et al.HBsAg may reappear following reactivation in individuals with spontaneous HBsAg seroclearance 8 years previously. Epidemiol Infect,2017,145(4):728-738.
[29] 庄辉. 乙型肝炎治愈的现状与进展. 中华肝脏病杂志,2018,26(8):561-564. |
